Rigel Pharmaceuticals RIGL
$40.09 −$1.10 (-2.67%)
Market closed · Nov 21, 9:10 am ET · Last extended-hours $40.00 -0.22%
Open$40.65
Prev close$41.19
Day range$39.62 – $41.66
Volume352.2K
Market cap$754.89M
P/E (TTM)2.5
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$80.89M+16.5% YoY
Operating profit$17.11M-39.8% YoY
Net profit$13.19M-52.7% YoY
Diluted EPS$0.65-55.5% YoY
Free cash flow$34.35M+43.0% YoY
Operating cash flow$34.56M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Gross margin89.6%
Operating margin26.3%
Net margin106.6%
Return on equity109.2%
Return on assets80.2%
Return on invested capital97.4%
Current ratio2.39
Liabilities / assets15.0%
Cash & investments$99.31M
Total debt$7.24M
Net cash (debt)$92.07M
Free cash flow / sales6.7%
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $80.89M | $78.70M | $58.82M | $294.28M | $69.80M |
| Total Operating Revenue | $80.89M | $78.70M | $58.82M | $294.28M | $69.80M |
| Cost of Revenue | $10.78M | $8.53M | $4.61M | $19.62M | $5.96M |
| Gross Profit | $70.11M | $70.18M | $54.21M | $274.66M | $63.85M |
| Operating Expense | $53.00M | $46.60M | $42.33M | $149.20M | $40.68M |
| Selling and Admin Expenses | $34.73M | $32.64M | $30.65M | $115.90M | $29.99M |
| Research & Development | $18.27M | $13.96M | $11.68M | $33.30M | $10.69M |
| Operating Profit | $17.11M | $23.58M | $11.89M | $125.47M | $23.17M |
| Net Non-Operating Interest Income (Expense) | $304,000.00 | $10,000.00 | -$228,000.00 | -$3.64M | -$456,000.00 |
| Non-Operating Interest Income | $561,000.00 | $789,000.00 | $1.21M | $3.68M | $1.24M |
| Non-Operating Interest Expense | $257,000.00 | $779,000.00 | $1.43M | $7.32M | $1.70M |
| Pretax Profit | $17.41M | $23.59M | $11.66M | $121.83M | $22.71M |
| Tax | $4.22M | $6.30M | $3.00M | -$245.20M | -$245.35M |
| Net Profit | $13.19M | $17.29M | $8.65M | $367.02M | $268.07M |
| Profit from Continuing Operations | $13.19M | $17.29M | $8.65M | $367.02M | $268.07M |
| Net Income to Parent Company | $13.19M | $17.29M | $8.65M | $367.02M | $268.07M |
| Net Income to Common Stockholders | $13.19M | $17.29M | $8.65M | $367.02M | $268.07M |
| Basic EPS | $0.70 | $0.93 | $0.47 | $20.40 | $14.72 |
| Diluted EPS | $0.65 | $0.88 | $0.44 | $19.48 | $13.54 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $523.88M | $521.07M | $504.61M | $513.59M | $513.59M |
| Total Current Assets | $188.52M | $185.53M | $234.03M | $240.17M | $240.17M |
| Cash and Cash Equivalents & Short-Term Investments | $99.31M | $95.33M | $146.68M | $154.96M | $154.96M |
| -Cash and Cash Equivalents | $46.65M | $60.82M | $24.41M | $40.58M | $40.58M |
| -Short Term Investments | $52.66M | $34.51M | $122.27M | $114.38M | $114.38M |
| Receivables | $56.46M | $56.04M | $49.95M | $51.76M | $51.76M |
| -Accounts Receivable | $56.46M | $56.04M | $49.95M | $51.76M | $51.76M |
| Prepaid Assets | $10.46M | $14.77M | $18.61M | $16.74M | $16.74M |
| Inventory | $15.81M | $14.37M | $11.65M | $11.51M | $11.51M |
| Other Current Assets | $6.49M | $5.03M | $7.14M | $5.21M | $5.21M |
| Total Non-Current Assets | $335.35M | $335.54M | $270.58M | $273.43M | $273.43M |
| Net PPE | $504,000.00 | $647,000.00 | $785,000.00 | $920,000.00 | $920,000.00 |
| -Gross PPE | $504,000.00 | $647,000.00 | $785,000.00 | $920,000.00 | $920,000.00 |
| Goodwill and Other Intangible Assets | $94.59M | $93.88M | $24.16M | $24.75M | $24.75M |
| Non-Current Deferred Assets | $234.53M | $238.07M | $243.28M | $245.85M | $245.85M |
| Other Non-Current Assets | $5.74M | $2.94M | $2.36M | $1.91M | $1.91M |
| Total Liabilities | $78.77M | $95.64M | $104.71M | $122.11M | $122.11M |
| Total Current Liabilities | $78.77M | $95.59M | $89.49M | $99.24M | $99.24M |
| Payables | $11.44M | $4.01M | $4.49M | $7.19M | $7.19M |
| -Accounts Payable | $11.44M | $4.01M | $4.49M | $7.19M | $7.19M |
| Current Accrued Expenses | $22.60M | $14.88M | $15.42M | $15.64M | $15.64M |
| Short-Term Debt and Capital Lease Obligation | $7.79M | $39.89M | $30.50M | $30.43M | $30.43M |
| -Current Debt | $7.24M | $39.24M | $29.87M | $29.81M | $29.81M |
| -Current Capital Lease Obligation | $556,000.00 | $656,000.00 | $636,000.00 | $614,000.00 | $614,000.00 |
| Current Deferred Liabilities | $26.81M | $27.97M | $28.08M | $29.07M | $29.07M |
| Total Non-Current Liabilities | $0.00 | $58,000.00 | $15.22M | $22.88M | $22.88M |
| Long Term Debt and Capital Lease Obligation | $0.00 | $58,000.00 | $15.22M | $22.88M | $22.88M |
| -Long Term Capital Lease Obligation | $0.00 | $58,000.00 | $228,000.00 | $395,000.00 | $395,000.00 |
| Total Equity | $445.11M | $425.42M | $399.90M | $391.48M | $391.48M |
| Stockholders' Equity | $445.11M | $425.42M | $399.90M | $391.48M | $391.48M |
| Capital Stock | $19,000.00 | $18,000.00 | $18,000.00 | $18,000.00 | $18,000.00 |
| -Common Stock | $19,000.00 | $18,000.00 | $18,000.00 | $18,000.00 | $18,000.00 |
| Additional Paid-In Capital | $1.43B | $1.42B | $1.41B | $1.41B | $1.41B |
| Retained Earnings | -$983.91M | -$997.10M | -$1.01B | -$1.02B | -$1.02B |
| Gains/Losses Not Affecting Retained Earnings | -$308,000.00 | -$148,000.00 | -$128,000.00 | $181,000.00 | $181,000.00 |
| Other Current Liabilities | – | $218,000.00 | $5.00M | $5.00M | $5.00M |
| -Long Term Debt | – | – | $14.99M | $22.48M | $22.48M |
| -Preferred Stock | – | – | – | $0.00 | $0.00 |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | $34.56M | $30.65M | $2.73M | $75.66M | $21.98M |
| Net cash flow from continuing operations | $34.56M | $30.65M | $2.73M | $75.66M | $21.98M |
| Net Income from Continuing Operations | $13.19M | $17.29M | $8.65M | $367.02M | $268.07M |
| Gain/Loss from Continuing Operations | $0.00 | – | – | – | – |
| Depreciation & Depletion & Amortization | $1.79M | $848,000.00 | $597,000.00 | $2.42M | $601,000.00 |
| Deferred Tax | $3.54M | $5.21M | $2.57M | -$245.85M | -$245.85M |
| Change in Working Capital | $11.23M | $286,000.00 | -$12.39M | -$19.51M | -$3.34M |
| -Change in Receivables | -$417,000.00 | -$6.10M | $1.82M | -$10.15M | -$5.84M |
| -Change in Inventory | -$4.18M | -$3.26M | -$581,000.00 | -$5.64M | $1.13M |
| -Change in Prepaid Assets | $2.84M | $5.97M | -$3.79M | -$11.85M | -$3.39M |
| -Change in Payables and Accrued Expense | $12.65M | $1.19M | -$4.28M | $5.30M | $5.51M |
| -Change in Other Current Assets | $143,000.00 | $138,000.00 | $135,000.00 | -$674,000.00 | $130,000.00 |
| -Change in Other Current Liabilities | -$158,000.00 | -$150,000.00 | -$145,000.00 | $439,000.00 | -$426,000.00 |
| -Change In Other Working Capital | $352,000.00 | $2.50M | -$5.54M | $3.05M | -$455,000.00 |
| Net cash flow from investing | -$18.45M | $17.45M | -$7.98M | -$92.37M | -$25.36M |
| Net Cash Flow from Continuing Investing Activities | -$18.45M | $17.45M | -$7.98M | -$92.37M | -$25.36M |
| Net Intangibles Purchase and Sale | -$217,000.00 | – | – | $0.00 | $0.00 |
| Net Investment Purchase and Sale | -$18.23M | $87.80M | -$7.98M | -$92.37M | -$25.37M |
| Financing Cash Flow | -$30.29M | -$11.70M | -$10.92M | $601,000.00 | -$4.57M |
| Net Cash Flow from Continuing Financing Activities | -$30.29M | -$11.70M | -$10.92M | $601,000.00 | -$4.57M |
| Net Issuance Payments Of Debt | -$32.00M | -$7.75M | -$7.50M | -$7.50M | -$7.50M |
| Net Common Stock Issuance | -$6.02M | -$511,000.00 | -$3.74M | $0.00 | $0.00 |
| Proceeds from Stock Option Exercised | $2.78M | $1.86M | $321,000.00 | $8.10M | $2.93M |
| Net Other Financing Charges | $4.96M | – | – | – | – |
| Ending Cash Balance | $46.70M | $60.87M | $24.47M | $40.64M | $40.64M |
| Net Change in Cash | -$14.17M | $36.41M | -$16.17M | -$16.11M | -$7.95M |
| Beginning Cash Balance | $60.87M | $24.47M | $40.64M | $56.75M | $48.59M |
| Free Cash Flow | $34.35M | -$39.69M | $2.73M | $75.66M | $21.99M |
| Other Non-Cash Items | – | – | – | -$39.98M | $0.00 |
| Capital Expenditure | – | – | – | $0.00 | $12,000.00 |
| Net PPE Purchase and Sale | – | – | – | $0.00 | $0.00 |
No comments yet — be the first to weigh in on RIGL.
Sign in to join the discussion.